Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The SOUND-MCL Study: A Single-arm, Open-label, Multicenter, Phase II Study of Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain

NCT07029737 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07029737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07029737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The SOUND-MCL Study: A Single-arm, Open-label, Multicenter, Phase II Study of Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Recruiting
Start date
September 5, 2025
Completion date
June 30, 2029
Enrollment
55 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

mantle-cell lymphoma